NPM1 and acute myeloid leukemia: The last observation is of particular interest, as 40% of AML patients exhibiting NPM1 mutations concurrently contain FLT3–ITD mutations and this is associated with early relapse and poorer prognosis compared with AML patients with NPM1 mutations only.12, 21